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ABSTRACT
Fentanyl is a potent synthetic opioid analgesic. However, due to its several limitations, new analogues are 
being synthesised for better pain management. We have earlier reported the synthesis and bio-efficacy of fentanyl 
and its eight new analogues (1-8) in mice. Among eight analogues tested, N-(1-(2-phenoxyethyl)-4-piperidinyl)
propionanilide (2), N-isopropyl-3-(4-(N-phenylpropionamido)piperidin-1-yl)propanamide (5), and N-t-butyl-3-(4-
(N-phenylpropionamido)piperidin-1-yl)propanamide (6) were found to be more effective and less toxic compared 
to fentanyl. Therapeutic efficacy of fentanyl and its analogues are known to be compromised due to many adverse 
effects, including alterations in the immune system. Therefore, the present study was undertaken to assess the acute 
effect of fentanyl and its three analogues (2, 5, and 6) on plasma levels of different pro-inflammatory cytokines 
such as interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), and anti-inflammatory 
cytokines such as interleukin-10 (IL-10) at different time points. Mice were intraperitoneally treated with 0.50 
LD
50
 of the compounds and cytokines were measured 1 h, 2 h, 4 h, and 24 h post-exposure. Compared to control, 
none of the treatments produced any change in TNF-α and IL-1β levels. However, IL-6 levels were significantly 
elevated between 1 h to 2 h post-exposure in fentanyl and analogue 2 treated groups. Further, IL-10 levels were 
found to be significantly increased in fentanyl, analogue 2, and 6 treated groups at 1 h and 2 h post-exposure. Pre-
treatment of naltrexone (opioid receptor antagonist) blocked the effects of fentanyl, confirming that its effects were 
opioid receptor- dependent. However, effect of naltrexone on analogue 2 and 6 was not conclusively evidenced, 
indicating that immunomodulatory changes caused by the analogues could have some additional implications as 
well. The present study reveals undesirable effects of fentanyl and its new analogues on cytokines homeostasis, 
thereby limiting their use in pain management.
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1. INTRODUCTION
Management of excruciating pain in an out of hospital 
scenario is very crucial for the recovery of soldiers and their 
performance. Opioid analgesics are widely used for the 
treatment of severe and chronic pain. Fentanyl is a synthetic 
narcotic opioid analgesic agent, very similar to morphine. 
However, fentanyl has many advantages due to its rapid 
onset of action, short duration of action, minimal provocation 
of histamine release, and many-fold higher potency than 
morphine 1-2. This drug is a strong agonist of µ-opioid receptor 
(MOR), which is widely implicated in surgical analgesia and 
sedation3,4. The clinical use of fentanyl remained restricted due 
to its undesirable effects on central nervous system (CNS), like 
respiratory depression, sedation, nausea, muscle rigidity, and 
tolerance and addiction after prolonged use5,6. In addition, they 
modulate immune functions and cause immunosuppression6,7. 
Morphine and related opioids have many diverse effects on 
the immune system including suppression of cell mediated, 
humoral-mediated, and natural (nonspecific) immunity. Many 
of the effects of opioids on immune system are indirect and 
appear to be mediated through the CNS, suggesting that 
alterations in opioid neurotransmission can alter the efficacy 
of the immune response7-9. Cytokines are low molecular 
weight proteins, which modulate cell growth, maturation, 
and intercellular communication of immune-competent cells7. 
Cytokines include chemokines, interferons, interleukins, 
lymphokines, and tumor necrosis factor. It has been reported 
that pro-inflammatory cytokines such as interleukin-1β (IL-
1β), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and 
anti-inflammatory cytokines such as interleukin-10 (IL-10) 
increase in patients with sepsis, trauma, and burns. Moreover, 
these cytokines are associated with the development of septic 
shock and organ dysfunction10.
Synthesis and comparative bioassay of fentanyl and its 
1-substituted analogues (1-8) in mice were earlier reported by 
us11,12. Out of these eight compounds, N-(1-(2-phenoxyethyl)-
4-piperidinyl)propionanilide (2), N-isopropyl-3-(4-(N-
phenylpropionamido)piperidin-1-yl)propanamide (5), and 
N-t-butyl-3-(4-(N-phenylpropionamido)piperidin-1-yl)
propanamide (6) were found to be more effective and less toxic Received : 04 May 2017, Revised : 03 October 2017
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compared to fentanyl. Different opioids have different degree 
of immunomodulation. Therefore, evaluating each opioid’s 
profile is important for appropriate analgesic selection13. The 
aim of the present study was to determine the acute effect 
of fentanyl and its three analogues viz., analogue 2, 5, and 
6 on plasma levels of different pro-inflammatory and anti-
inflammatory cytokines at different time points, with a view to 
see the immunomodulatory effects of these compounds.
2. MATERIALS AND METHODS
2.1 Animals
Male Swiss albino mice (25-30 g) were procured from 
the Animal Facility of Defence Research and Development 
Establishment (DRDE), Gwalior. The animals were housed 
in polypropylene cages on dust free rice husk as the bedding 
materials, with free access to food (Ashirwad Brand, 
Chandigarh, India) and water ad libitum. Prior to experiment, 
animals were randomised and acclimatised for seven days 
in controlled environmental conditions (22±2°C; relative 
humidity 40 % - 60 %) at a 12 h light/12 h dark cycle. The 
care and maintenance of the animals were as per the approved 
guidelines of the Committee for the Purpose of Control and 
Supervision of Experiments on Animals (CPCSEA), India. 
Animal experiments were carried out with the approval of 
Institutional Animal Ethical Committee.
2.2 Chemicals
Naltrexone hydrochloride and dimethyl sulfoxide 
(DMSO) were purchased from Sigma-Aldrich (St. Louis, 
uSA). Fentanyl and its 1-substituted analogues (2, 5, and 6) 
were synthesised and characterised by IR, 1H NMR, 13C NMR, 
GC-MS and elemental analysis in the Synthetic Chemistry 
Division of DRDE, Gwalior as per the methods discussed 
elsewhere11,12. The structures of the compounds are as follows:
    
and blood was collected at 1 h, 2 h, 4 h, and 24 h post-exposure 
for measurement of various cytokines. Blood was drawn 
from the retro-orbital plexus ether anesthetised animals using 
haparinised capillary. In a separate study, forty eight mice were 
divided into four groups of twelve animals each as follows: 
(1) Control (DMSO), (2) fentanyl (0.50 LD
50
) + naltrexone, 
(3) analogue 2 (0.50 LD
50
) + naltrexone, (4) analogue 6 (0.50 
LD
50
) + naltrexone. Naltrexone (10 mg/kg) was subcutaneously 
(s.c.) administered 30 min prior to treatment with fentanyl or 
analogues. Six animals were randomly selected from each 
group for each time point and blood was collected 1 h and 2 h 
post-exposure for measurement of cytokines. The dose, route, 
and time of naltexone hydrochloride were selected on the 
basis of previous study9. Furthermore, Houghtling and Bayer9 
reported that naltrexone pre-treatment had no effect on plasma 
cytokines. Therefore, in the present study a separate group for 
naltrexone was not used.
2.4 Measurement of Cytokines
Various cytokines such as tumor necrosis factor alpha 
(TNF-α; pg/ml), interleukin-1β (IL-1β; pg/ml), interleukin-6 
(IL-6; pg/ml), and interleukin-10 (IL-10; pg/ml) were measured 
in blood plasma using Enzyme Linked Immunosorbent Assay 
(ELISA) kits (Thermo Scientific, Rockford, uSA) as per 
manufacturer’s protocol, using Multimode Microplate Reader 
(Synergy 4, BioTek Instruments, VT, uSA).
2.5 Statistics
The results are expressed as mean ± SEM (n=6). The data 
were analysed by one way ANOVA followed by Dunnet’s test. 
Statistical significance was drawn at *p<0.05 and **p<0.01 
levels using SigmaStat software (Jandel Scientific Inc., CA, 
uSA).
3. RESULTS
In the present study, the immunomodulatory effect 
of fentanyl and its analogues (2, 5, and 6) was assessed by 
measuring both pro-inflammatory (TNF-α, IL-1β, IL-6) 
and anti-inflammatory cytokine (IL-10) in plasma of treated 
animals at various time points. Figures 1 and 2 show the effect 
of fentanyl and its analogues on TNF-α and IL-1β levels, 
respectively. There was no significant difference observed in 
TNF-α and IL-1β levels between the control and treated groups. 
The IL-6 levels were significantly increased in fentanyl and 
analogue 2 treated groups 1 and 2 h post-exposure as shown 
in Fig. 3. The IL-10 levels were found to be significantly 
increased in fentanyl, analogue 2 and 6 treated groups 1 and 
2 h post-exposure as shown in Fig. 4.
In order to determine whether the elevation of plasma 
IL-6 (fentanyl, analogue 2) and IL-10 (fentanyl, analogue 2 
and 6) was mediated through the activation of opioid receptors, 
the animals were pre-treated (-30 min) with opioid receptor 
antagonist naltrexone9. Pre-treatment of naltrexone was found 
to block the elevation of IL-6 as shown in Fig. 5 and IL-10 
as shown in Fig. 6. in fentanyl treated group. However, the 
increased levels of IL-6 in analogue 2 treated as shown in 
Fig. 5 and IL-10 in analogue 2 and 6 treated groups as shown 
in Fig. 6 continued to persist.
2.3 Treatment
One hundred twenty mice were divided into five groups 
of twenty four animals each as follows: (1) Control (DMSO), 
(2) fentanyl (3) analogue 2 (4) analogue 5, and (5) analogue 6. 
All the compounds were dissolved in DMSO and administered 
intraperitoneally (i.p.) in a volume <10 ml/kg body weight. 
The doses of fentanyl and its analogues were equivalent to 
their respective 0.50 LD
50
 (i.p.) values, which were 8.75 
mg/kg (fentanyl), 56.10 mg/kg (analogue 2), 56.90 mg/kg 
(analogue 5), and 53.65 mg/kg (analogue 6)11,12. Six animals 
were randomly selected from each group for each time point 
Analogue 2
Analogue 5
Fentanyl    
Analogue 6
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Figure 1. Male mice were intraperitoneally treated with fentanyl and its analogues 2, 5, and 6 (0.50 LD50). Plasma levels of TNF-a 
were measured 1 h, 2 h, 4 h, and 24 h post- exposure. Values are mean ± SEM (n=6).
Figure 2. Male mice were intraperitoneally treated with fentanyl and its analogues 2, 5, and 6 (0.50 LD50) . Plasma levels of IL-Ib 
were measured 1 h, 2 h, 4 h, and 24 h post-exposure. Values are mean ± SEM (n=6). 
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Figure 3. Male mice were intraperitoneally treated with fentanyl and its analogues 2, 5, and 6 (0.50 LD50). Plasma levels of IL-6 
were measured 1 h, 2 h, 4 h, and 24 h post-exposure. Values are mean ± SEM (n=6). Statistical significance was drawn 
at **p<0.01.
Figure 4. Male mice were intraperitoneally treated with fentanyl and its analogues 2, 5, and 6 (0.50 LD50) . Plasma levels of IL- 10 
were measured 1 h, 2 h, 4 h, and 24 h post-exposure. Values are mean ± SEM (n=6). Statistical significance was drawn at 
*p<0.05 and **p<0.01. 
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Figure 5. Male mice received pre-treatment (-30 min) of 
naltrexone hydrochloride (10 mg/kg; subcutaneous) 
followed by intraperitoneal injection of fentanyl or 
analogue 2 (0.50 LD50). Plasma levels of IL-6 were 
measured 1 h and 2 h post-exposure. Values are mean 
± SEM (n=6). Statistical significance was drawn at 
**p<0.01.
Figure 6. Male mice received pre-treatment (-30 min) of 
naltrexone hydrochloride (10 mg/kg; subcutaneous) 
followed by intraperitoneal injection of fentanyl or 
analogue 2 and 6 (0.50 LD50). Plasma levels of IL-10 
were measured 1 h and 2 h post-exposure. Values 
are mean ± SEM (n=6). Statistical significance was 
drawn at *p<0.05 and **p<0.01.
IL-6 is produced by both immune and non-immune tissues and 
hence has numerous different biological effects. For instance, 
circulating IL-6 leads to the release of acute phase proteins 
from the liver15, elicits a febrile response and activates the 
hypothalamic-pituitary-adrenal axis (HPA axis)16. Illicit or 
therapeutic use of opioids could lead to a dysregulation of 
circulating IL-6 levels. In our present study, IL-6 levels were 
increased in fentanyl and analogue 2 treated groups 1 h and 
2 h post-exposure. Moreover, increases in IL-6 levels were 
more prominent in the analogue 2 treated group compared to 
fentanyl. Previous study also showed a significant increase in 
plasma IL-6 up to 2 h after morphine administration (10 mg/kg, 
s.c.) in rats9. It has been demonstrated that opioids can affect the 
cells of immune system directly through the opioid receptors 
on lymphocytes and macrophages17. Moreover, opiates can 
regulate the functions of the immune system through the 
nervous system9,18. It has been shown that increased production 
of IL-6 depends on the activity of the HPA axis and can be 
blocked by adrenalectomy9.
4. DISCUSSION
Opioids have a variety of effects on the immune system. 
Recently much attention has been emphasised on opioids and 
its impact on the immune system13,14. Opioids have been shown 
to modulate immune function by direct effects on cells of the 
immune system and indirectly via centrally mediated neuronal 
mechanisms6. In the present study, the immunomodulatory 
effect of fentanyl and its analogues was estimated in terms of 
cytokine levels in the blood plasma. In our present study, no 
significant change was observed in TNF-α and IL-1β levels in 
fentanyl and its analogues treated groups. In a previous study, 
incubation of whole blood in the presence of lipopolysaccharide 
(LPS) demonstrated a significant increase in TNF-α level in 
fentanyl treated group and, incubation of whole blood in the 
absence of LPS did not result in altered levels of TNF-α7. In 
this study, Wu7, et al. demonstrated that fentanyl suppressed 
LPS-induced cytokines production. Moreover, they advocated 
that fentanyl modulates immune function directly through 
binding to the MOR present on cells of the immune system. 
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In the present study, the anti-inflammatory cytokine IL-10 
was found to significantly increase in fentanyl and analogue 
2, and 6 treated group up to 2 hr. Our results are in agreement 
with previous studies where a significant increase in IL-10 was 
observed in patients undergoing coronary artery bypass graft 
after sufentanil and fentanyl anesthesia19. However, in another 
study a significant decrease in IL-10 levels were observed in 
spleen cells after heroin administration20. There are conflicting 
reports on anti- or pro-inflammatory properties of μ-opioids21. 
For instance, morphine inhibits carrageenan-induced paw 
swelling22 and was able to attenuate adjuvant arthritis in rats 
near toxic doses23,24. Conversely, low doses of morphine 
were pro-inflammatory in adjuvant arthritis25. Different 
opioids show different effects on the immune system such 
as immunostimulatory, immunosuppressive, or dual effect26. 
However, how they affect the different cytokines is not well 
defined27. Immunosuppressive activity depends on the type of 
the opioid, independent of the potency or the duration of action28. 
Moreover, Liang26, et al. advocated that administration of short 
term/ low dose opioid has a positive impact and administration 
of long term/ high dose opioid has a negative impact on the 
immune system. In previous study, analogue 2, 5 and 6 were 
found to produce respiratory depression in a dose- dependent 
manner, which was similar to that caused by fentanyl29.
In order to ascertain the involvement of opioid receptor, 
pre-treatment of naltrexone was used. We observed that in 
fentanyl treated group, elevation of plasma IL-6 and IL-10 levels 
was completely blocked by pre-treatment with naltrexone, thus 
demonstrating that this effect of fentanyl is opioid receptor-
dependent. Here, our observations are in agreement with 
previous studies suggesting a role for opioid receptors in 
the elevation of serum IL-6 after morphine administration9. 
However, in analogue 2 treated group elevation of IL-6, and IL-
10 and in analogue 6 treated group, elevation of IL-10 were not 
blocked by naltrexone. This indicates that immunomodulatory 
changes caused by analogue 2 and 6 could have some additional 
implications as well. The most probable reason for this is that 
exogenous opioids exert effects through multiple types of 
receptors30. Furthermore, Pacifici30, et al. observed that central 
opioid or non-opioid receptors are involved in exogenous 
opioid-induced stimulatory effects, whereas peripheral opioid 
or non-opioid receptors are involved in depressive effects.
5. CONCLUSIONS
Opioid analgesics are known to exhibit diverse 
immunomodulatory properties. In our present study, fentanyl 
and its analogue 2 and 6 were found to significantly alter the 
levels of various cytokines at 0.50 LD
50 
(i.p.), which could be 
construed as undesirable effect in pain management. However, 
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